story of the week
Adjuvant Capecitabine Plus Bevacizumab vs Capecitabine Alone in Patients With Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Capecitabine Plus Bevacizumab Versus Capecitabine Alone in Patients With Colorectal Cancer (QUASAR 2): An Open-Label, Randomised Phase 3 Trial
Lancet Oncol 2016 Sep 19;[EPub Ahead of Print], RS Kerr, S Love, E Segelov, E Johnstone, B Falcon, P Hewett, A Weaver, D Church, C Scudder, S Pearson, P Julier, F Pezzella, I Tomlinson, E Domingo, DJ KerrFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.